The DOI matches its Crossref record.
Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia.
Abstract
Abstract 790 Study S0106 is an open-label randomized phase III trial to evaluate the benefit and toxicity of adding Gemtuzumab ozogamicin [GO] to standard induction therapy, followed by a post-consolidation randomization to receive either 3 additional doses of GO or no additional therapy [OBS]. Eligible patients were adults (age 18-60) with previously untreated de novo nonM3 AML. Patients were randomized (stratified by age <35 vs 35+) to receive induction therapy with daunorubicin (45 mg/m2 D1,2,3) and cytarabine (100mg/m2/d CI D1-7) and GO (6 mg/m2 D4) [AD+GO] (DeAngelo,2003) versus standard induction therapy with daunorubicin (60 mg/m2 IV D1,2,3) and cytarabine (100mg/m2/d CI D1-7) [AD]. Patients in either arm who failed to achieve aplasia at D14 were retreated with AD. Patients achieving CR received consolidation therapy with 3 courses of high dose cytarabine (3 gm/m2/q12h D1,3,5 every 28 days). Patients remaining in CR after consolidation were eligible for a second randomization (stratified by cytogenetic risk category at diagnosis and use of GO during induction) between 3 doses of GO (5 mg/m2 every 28 days) or OBS. 627 patients were registered on study S0106 from May 15, 2004 though July 23, 2009, the cutoff for the second interim analysis of induction outcomes (which by protocol plan was based on the first 456 eligible patients) and first planned interim analysis of disease-free survival measured from the post-consolidation randomization [DFS] (based on the first 64 relapses or deaths). Complete response [CR] rates were 150/277=66% (AD+GO) and 159/229=69% (AD), ruling out the originally hypothesized 12% increase with AD+GO at the prespecified significance level (P<0.0025). Including CRs with incomplete hematologic recovery, the response rates were 74% in both arms. Importantly, relapse-free survival measured from the date of CR [RFS] was not significantly better in the AD+GO arm (hazard ratio [HR]=1.00, 95% confidence interval [CI] 0.69-1.44, P=0.50), unlike preliminary results of the MRC AML15 trial (Burnett, Blood 2006 108: Abstract 13). Among all patients evaluable for induction toxicity, the rate of fatal adverse events [AEs] at least possibly attributable to treatment (most commonly hemorrhage, infection and/or ARDS) was significantly higher in the AD+GO arm (15/260=5.8% vs 2/255=0.8%, P=0.002). One death in the AD+GO arm was attributable to sinusoidal obstruction syndrome (SOS). Notably, the AE rate in the AD+GO arm is similar to previous SWOG AML trials, while the rate in the AD arm is remarkably low (CI 0.1-2.8%). The first planned interim analysis of post-consolidation therapy evaluated 150 patients randomized between GO and OBS, only 7 of whom had unfavorable cytogenetics. 36 GO and 25 OBS patients have relapsed, and one GO and 2 OBS patients have died without report of relapse. DFS was not significantly better in the GO arm (HR=0.66 for OBS compared to GO, CI 0.40-1.08, one-sided P=0.95); moreover the hypothesized benefit of GO (HR=1.5) was rejected at the prespecified significance level (P<0.001). Based on these results – the lack of improvement in CR rate or RFS and the higher fatal induction AE rate on the AD+GO induction arm, and the lack of improvement in DFS on the post-consolidation GO arm – the SWOG DSMC on August 11, 2009 recommended closure of both the induction and post-consolidation randomizations. Among all eligible patients with any follow-up, the estimated median overall survival from study entry was 31 months with AD+GO induction (CI 22-39 months) and 35 months with AD (CI 24-41 months). In this study, the addition of GO to induction therapy or as post-consolidation therapy did not improve the CR rate, RFS, post-consolidation DFS, or overall survival, but was associated with a significantly higher risk of fatal induction adverse events. Disclosures: No relevant conflicts of interest to declare.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00947-7 · Cited by 1,643
Castaigne, S., Pautas, C., Terré, C., Raffoux, E., Bordessoule, D., Bastie, J.-N., Legrand, O., Thomas, X., Turlure, P., Reman, O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60485-1 · Cited by 1,015
Antibody-Drug Conjugates in Cancer Therapy
Sievers, E. L., & Senter, P. D. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-050311-201823 · Cited by 770
Senter, P. D., & Sievers, E. L. (2012) · Nature Biotechnology · doi:10.1038/nbt.2289 · Cited by 763
Site-specific antibody drug conjugates for cancer therapy
Panowski, S., Bhakta, S., Raab, H., Polakis, P., & Junutula, J. R. (2014) · mAbs · doi:10.4161/mabs.27022 · Cited by 676
Metadata
- Authors
- Petersdorf, S., Kopecky, K., Stuart, R. K., Larson, R. A., Nevill, T. J., Stenke, L., Slovak, M. L., Tallman, M. S., Willman, C. L., Erba, H., & Appelbaum, F. R.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2009-11-20
- Volume
- 114
- Issue
- 22
- Pages
- 790-790
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2546853358
- Cited by
- 184
- References
- 0
- FWCI
- 16.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia. https://app.cochat.ai/papers/10.1182/blood.v114.22.790.790
- The paper
- Petersdorf, S., Kopecky, K., Stuart, R. K., Larson, R. A., Nevill, T. J., Stenke, L., Slovak, M. L., Tallman, M. S., Willman, C. L., Erba, H., & Appelbaum, F. R. (2009). Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia. Blood. https://doi.org/10.1182/blood.v114.22.790.790
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.